Visit our FAQ
Toll Free Phone (USA and Canada Only): (888) 526-5351
Direct Phone: (734) 975-3888
Product Categories
Provide batch numbers separated by commas to download or request available product inserts, QC sheets, certificates of analysis, data packs, and GC-MS data.

CHS-828 is a nicotinamide phosphoribosyltransferase (Nampt) inhibitor (IC50 = <25 nM).1 It selectively inhibits Nampt over nicotinamide/nicotinic acid mononucleotide adenylyltransferase 1 (NMN/NaMN adenylyltransferase 1) at 10 µM. CHS-828 (100 nM) reduces NAD+ levels in, and is cytotoxic to, HeLa cervical cancer cells. It decreases ATP levels in C666-1 nasopharyngeal and FaDu head and neck squamous cell carcinoma (HNSCC) cells in a time-dependent manner when used at concentrations of 10 and 20 nM, respectively.2 CHS-828 (100 and 250 mg/kg per week) reduces tumor growth in MCF-7 breast cancer and NYH small cell lung cancer mouse xenograft models.3
WARNING This product is not for human or veterinary use.
1. The small molecule GMX1778 is a potent inhibitor of NAD+ biosythesis: Strategy for enhanced therapy in nicotinic acid phophoribosyltransferase 1-
2. Efficacy of combining GMX1777 with radiation therapy for human head and neck carcinoma. Clin. Cancer Res. 16(3), 898-911 (2010).
3. CHS 828, a novel pyridyl cyanoguanidine with potent antitumor activity in vitro and in vivo. Cancer Res. 59(22), 5751-5757 (1999).